림프절 양성 유방암의 선행항암화학요법 후 잔여 액와부 림프절 전이의 예측 인자
Predictive Factors of Residual Metastatic Axillary Lymph Nodes after Neoadjuvant Chemotherapy in Node-Positive Breast Cancer
2
조회
0
다운로드
1
인용
0
참고문헌
키워드
초록
Purpose: Sentinel lymph node biopsy (SLNB) has been a reliable technique in breast cancer staging. However, some authors reported that SLNB after neoadjuvant chemotherapy (NAC) could lead to low identification rates and high false-negative rates. Hence, whether only SLNB can be applied after NAC is controversial. The aim of this study was to identify predictive factors of residual metastatic axillary lymph nodes after NAC. Methods: In this study, 71 breast cancer patients with clinically positive lymph nodes (cN1), who received axillary lymph node dissection (ALND) after NAC between July 2012 and September 2014, were enrolled. The patients were divided into N1 and N0 groups according to the presence of residual axillary metastatic lymph nodes after ALND. We compared the clinical, radiological, and immunohistological factors between two groups. Results: In the 71 patients with cN1who received NAC, N1 and N0 status were confirmed after surgery in 43 and 28 patients, respectively. The clinical stage at diagnosis was IIA in one patient, IIB in 15 patients, IIIA in 35 patients, IIIB in two patients, IIIC in 10 patients, and IV in eight patients. Most of the patients (n=57) received eight cycles (four cycles of anthracycline and four of taxane) of chemotherapy. Our study showed that the primary tumor was downstaged in 58 of the 71 patients (81.7%). Sixteen patients (22.5%) had pathological complete response (pCR) and 42 (59.2%) had pathological partial response. In a multivariate analysis, tumor response and human epidermal growth factor receptor 2 (HER2) were identified as significant factors. However, no significant differences were observed in the results of postchemotherapy ultrasonography, and pre- or post-positron emission tomography computed tomography (maximum standardized uptake value reduction). Conclusion: In the NAC setting, SLNB before ALND is feasible for tumors predicted to have a pCR or if target therapy had been administered for HER2-positive breast cancer.
Abstract
Purpose: Sentinel lymph node biopsy (SLNB) has been a reliable technique in breast cancer staging. However, some authors reported that SLNB after neoadjuvant chemotherapy (NAC) could lead to low identification rates and high false-negative rates. Hence, whether only SLNB can be applied after NAC is controversial. The aim of this study was to identify predictive factors of residual metastatic axillary lymph nodes after NAC. Methods: In this study, 71 breast cancer patients with clinically positive lymph nodes (cN1), who received axillary lymph node dissection (ALND) after NAC between July 2012 and September 2014, were enrolled. The patients were divided into N1 and N0 groups according to the presence of residual axillary metastatic lymph nodes after ALND. We compared the clinical, radiological, and immunohistological factors between two groups. Results: In the 71 patients with cN1who received NAC, N1 and N0 status were confirmed after surgery in 43 and 28 patients, respectively. The clinical stage at diagnosis was IIA in one patient, IIB in 15 patients, IIIA in 35 patients, IIIB in two patients, IIIC in 10 patients, and IV in eight patients. Most of the patients (n=57) received eight cycles (four cycles of anthracycline and four of taxane) of chemotherapy. Our study showed that the primary tumor was downstaged in 58 of the 71 patients (81.7%). Sixteen patients (22.5%) had pathological complete response (pCR) and 42 (59.2%) had pathological partial response. In a multivariate analysis, tumor response and human epidermal growth factor receptor 2 (HER2) were identified as significant factors. However, no significant differences were observed in the results of postchemotherapy ultrasonography, and pre- or post-positron emission tomography computed tomography (maximum standardized uptake value reduction). Conclusion: In the NAC setting, SLNB before ALND is feasible for tumors predicted to have a pCR or if target therapy had been administered for HER2-positive breast cancer.
참고문헌 (18)
- Kuehn T, "Sentinel-lymph-node biopsy in patients with breast cancer before and after neoadjuvant chemotherapy (SENTINA): a prospective, multicentre cohort study", Lancet Oncol, 14, pp.609~618 (2013)
- Boughey JC, "Sentinel lymph node surgery after neoadjuvant chemotherapy in patients with node-positive breast cancer: the ACOSOG Z1071 (Alliance) clinical trial", JAMA, 310, pp.1455~1461 (2013)
- 한아람, "Reliability of Sentinel Lymph Node Biopsy after Neoadjuvant Chemotherapy in Breast Cancer Patients", Journal of Breast Cancer, 16(4), pp.378~385 (2013), 한국유방암학회
- Nason KS, "Increased false negative sentinel node biopsy rates after preoperative chemotherapy for invasive breast carcinoma", Cancer, 89, pp.2187~2194 (2000)
- Wolmark N, "Preoperative chemotherapy in patients with operable breast cancer: nine-year results from National Surgical Adjuvant Breast and Bowel Project B-18", J Natl Cancer Inst Monogr, (30), pp.96~102 (2001)
- Fisher B, "Effect of preoperative chemotherapy on local-regional disease in women with operable breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project B-18", J Clin Oncol, 15, pp.2483~2493 (1997)
- Kuerer HM, "Incidence and impact of documented eradication of breast cancer axillary lymph node metastases before surgery in patients treated with neoadjuvant chemotherapy", Ann Surg, 230, pp.72~78 (1999)
- Park SH, "Comparison of diffusion-weighted MR imaging and FDG PET", CT to predict pathological complete response to neoadjuvant chemotherapy in patients with breast cancer, 2012, pp.22, 18~25
- Kumar A, "The role of 18F-FDG PET", CT in evaluation of early response to neoadjuvant chemotherapy in patients with locally advanced breast cancer, 2009, pp.19, 1347~1357
- Straver ME, "Feasibility of FDG PET", CT to monitor the response of axillary lymph node metastases to neoadjuvant chemotherapy in breast cancer patients, 2010, pp.37, 1069~1076
- Duch J, "18F-FDG PET", CT for early prediction of response to neoadjuvant chemotherapy in breast cancer, 2009, pp.36, 1551~1557
- Khan A, "Comprehensive axillary evaluation in neoadjuvant chemotherapy patients with ultrasonography and sentinel lymph node biopsy", Ann Surg Oncol, 12, pp.697~704 (2005)
- Reitsamer R, "Sentinel lymph node biopsy in breast cancer patients after neoadjuvant chemotherapy", J Surg Oncol, 84, pp.63~67 (2003)
- Kang SH, "Sentinel lymph node biopsy after neoadjuvant chemotherapy", Breast Cancer, 11, pp.233~241 (2004)
- Haid A, "Is sentinel lymph node biopsy reliable and indicated after preoperative chemotherapy in patients with breast carcinoma?", Cancer, 92, pp.1080~1084 (2001)
- Kinoshita T, "Sentinel lymph node biopsy is feasible for breast cancer patients after neoadjuvant chemotherapy", Breast Cancer, 14, pp.10~15 (2007)
- Xing Y, "Meta- analysis of sentinel lymph node biopsy after preoperative chemotherapy in patients with breast cancer", Br J Surg, 93, pp.539~546 (2006)
- Newman EA, "Sentinel lymph node biopsy performed after neoadjuvant chemotherapy is accurate in patients with documented node-positive breast cancer at presentation", Ann Surg Oncol, 14, pp.2946~2952 (2007)